ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,305,225 | -4.5% | 2,196,500 | +23.6% | 0.21% | +3.0% |
| Q2 2023 | $81,954,558 | -19.1% | 1,776,600 | -29.7% | 0.20% | -20.4% |
| Q1 2023 | $101,276,560 | -29.4% | 2,525,600 | -18.4% | 0.26% | -35.6% |
| Q4 2022 | $143,368,185 | -9.3% | 3,094,500 | -18.9% | 0.40% | -14.5% |
| Q3 2022 | $158,037,000 | -30.2% | 3,816,397 | +0.5% | 0.46% | -24.8% |
| Q2 2022 | $226,535,000 | -21.8% | 3,797,089 | -4.8% | 0.62% | -5.8% |
| Q1 2022 | $289,589,000 | -13.6% | 3,987,728 | +0.0% | 0.65% | +5.0% |
| Q4 2021 | $335,256,000 | -6.8% | 3,986,870 | -0.0% | 0.62% | -9.1% |
| Q3 2021 | $359,590,000 | -2.1% | 3,987,032 | +3.5% | 0.68% | +0.1% |
| Q2 2021 | $367,223,000 | -17.6% | 3,851,310 | -1.6% | 0.68% | -20.8% |
| Q1 2021 | $445,467,000 | -24.8% | 3,912,408 | -8.6% | 0.86% | -28.7% |
| Q4 2020 | $592,554,000 | +76.1% | 4,280,528 | +4.5% | 1.21% | +53.6% |
| Q3 2020 | $336,512,000 | +5.4% | 4,094,315 | +0.3% | 0.79% | -0.1% |
| Q2 2020 | $319,166,000 | +78.8% | 4,080,359 | +1.6% | 0.79% | +50.5% |
| Q1 2020 | $178,465,000 | +40.6% | 4,016,760 | +35.2% | 0.52% | +85.5% |
| Q4 2019 | $126,935,000 | +4.0% | 2,972,008 | +4.1% | 0.28% | -5.7% |
| Q3 2019 | $122,108,000 | +8.4% | 2,854,310 | +60.8% | 0.30% | +9.5% |
| Q2 2019 | $112,690,000 | -7.1% | 1,774,652 | +1.5% | 0.27% | -8.7% |
| Q1 2019 | $121,330,000 | +118.5% | 1,749,274 | +36.9% | 0.30% | +98.7% |
| Q4 2018 | $55,538,000 | -51.0% | 1,277,319 | -13.9% | 0.15% | -42.8% |
| Q3 2018 | $113,309,000 | +4.0% | 1,484,271 | +4.7% | 0.26% | -17.2% |
| Q2 2018 | $108,967,000 | +78.2% | 1,417,551 | +18.2% | 0.32% | +79.2% |
| Q1 2018 | $61,162,000 | +19.8% | 1,199,491 | +9.0% | 0.18% | +23.6% |
| Q4 2017 | $51,055,000 | +144.8% | 1,100,800 | +181.1% | 0.14% | +140.0% |
| Q3 2017 | $20,857,000 | -19.5% | 391,600 | -6.1% | 0.06% | -20.0% |
| Q2 2017 | $25,906,000 | -8.4% | 417,100 | 0.0% | 0.08% | -7.4% |
| Q1 2017 | $28,271,000 | -8.3% | 417,100 | -4.8% | 0.08% | -12.0% |
| Q4 2016 | $30,817,000 | -1.9% | 438,300 | -1.0% | 0.09% | +2.2% |
| Q3 2016 | $31,398,000 | +44.9% | 442,600 | -0.1% | 0.09% | +42.9% |
| Q2 2016 | $21,670,000 | -22.7% | 443,050 | 0.0% | 0.06% | -27.6% |
| Q1 2016 | $28,049,000 | -37.5% | 443,050 | +10.8% | 0.09% | -38.7% |
| Q4 2015 | $44,850,000 | +16.7% | 399,800 | +0.2% | 0.14% | +14.5% |
| Q3 2015 | $38,442,000 | -5.8% | 399,150 | +0.1% | 0.12% | +1.6% |
| Q2 2015 | $40,813,000 | +64.9% | 398,600 | 0.0% | 0.12% | +62.7% |
| Q1 2015 | $24,749,000 | +95.2% | 398,600 | +38.0% | 0.08% | +92.3% |
| Q4 2014 | $12,677,000 | -22.5% | 288,900 | 0.0% | 0.04% | -26.4% |
| Q3 2014 | $16,352,000 | +162.3% | 288,900 | +108.0% | 0.05% | +165.0% |
| Q2 2014 | $6,235,000 | -9.8% | 138,900 | -1.7% | 0.02% | -13.0% |
| Q1 2014 | $6,909,000 | – | 141,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |